menu
    • menu
    [{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kintor Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Kintor Pharmaceutical \/ IQVIA Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ IQVIA Biotech"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pyrilutamide","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pyrilutamide","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pyrilutamide","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Pyrilutamide

    Menu

    Pyrilutamide

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kintor Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Kintor Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenet...

                            Details : KX-826 (pyrilutamide) is a monoclonal antibody drug candidate with potential AR antagonistic action, is being developed as a potential topical drug for the treatment of androgenic alopecia and acne vulgaris.

                            Brand Name : KX-826

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 11, 2023

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kintor Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Kintor Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment o...

                            Details : KX-826 (pyrilutamide) is a monoclonal antibody drug candidate with potential AR antagonistic action, is being developed as a potential topical drug for the treatment of androgenic alopecia and acne vulgaris.

                            Brand Name : KX-826

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 28, 2023

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kintor Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Kintor Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Andro...

                            Details : KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. KX-826 has demonstrated clinically meaningful and statistically significant improvement in hair growth.

                            Brand Name : KX-826

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 01, 2022

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kintor Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Kintor Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Acne Vulgari...

                            Details : KX-826 (pyrilutamide) is an AR antagonist and a potential first-in-class topical drug for treatment of androgenetic alopecia and acne vulgaris continues to demonstrate good efficacy and safety in phase II clinical trial to benefit more people suffering f...

                            Brand Name : KX-826

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 16, 2022

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kintor Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Kintor Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : IQVIA

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kintor Announces 2022 Interim Results and Recent Business Update

                            Details : KX-826 (pruxelutamide) effectively reduced hospitalization/mortality; in particular, for subjects who completed the medication for more than 7 days and middle-and-high-age COVID-19 patients with high risk factors, the protection rate was 100%.

                            Brand Name : KX-826

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 29, 2022

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : IQVIA

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Kintor Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Kintor Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of...

                            Details : Kintor Pharma announced that the primary endpoint of the phase II clinical trial of KX-826 (pyrilutamide) on adult male patients was met, with results demonstrating a positive safety profile and good efficacy.

                            Brand Name : KX-826

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 03, 2022

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Kintor Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Kintor Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the...

                            Details : KX-826 is an androgen receptor antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. The primary endpoint of the phase II clinical trial of KX-826 on adult male patients was met, as results showed good efficac...

                            Brand Name : KX-826

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 06, 2022

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Kintor Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Kintor Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kintor Pharma Announces First Patient Dosing in Phase II Clinical Trial of KX-826 for Treatment of Androgenic ...

                            Details : KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. KX-826 has showed good efficacy and safety profile in the phase II clinical trial in China for the treatment of AGA mal...

                            Brand Name : KX-826

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 01, 2022

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Kintor Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Kintor Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kintor Pharma Receives IND Clearance by NMPA for KX-826’s Pivotal Study to Treat Male Alopecia Patients

                            Details : KX-826 (pyrilutamide) is first androgen receptor antagonist which has entered phase III clinical trial for male androgenetic alopecia treatment in China and global. Primary endpoint of KX-826 on male AGA patients met and demonstrated outstanding efficacy...

                            Brand Name : KX-826

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 24, 2021

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Kintor Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Kintor Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kintor Pharmaceuticals Sucessfully Dosed First Batch of Patients for Acne Vulgaris Phase I/II Clinical Trial o...

                            Details : The Phase I/II clinical trial in China is a randomized, double-blind, placebo-controlled clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of Pyrilutamide in patients with mild to moderate acne vulgaris.

                            Brand Name : KX-826

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 16, 2021

                            Lead Product(s) : Pyrilutamide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth